BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 30423193)

  • 1. Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers.
    Sundi D; Tosoian JJ; Nyame YA; Alam R; Achim M; Reichard CA; Li J; Wilkins L; Schwen Z; Han M; Davis JW; Klein EA; Schaeffer EM; Stephenson AJ; Ross AE; Chapin BF
    Cancer; 2019 Feb; 125(3):391-397. PubMed ID: 30423193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Very-high-risk localized prostate cancer: definition and outcomes.
    Sundi D; Wang VM; Pierorazio PM; Han M; Bivalacqua TJ; Ball MW; Antonarakis ES; Partin AW; Schaeffer EM; Ross AE
    Prostate Cancer Prostatic Dis; 2014 Mar; 17(1):57-63. PubMed ID: 24189998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary Gleason grade 4 at the positive margin is associated with metastasis and death among patients with Gleason 7 prostate cancer undergoing radical prostatectomy.
    Viers BR; Sukov WR; Gettman MT; Rangel LJ; Bergstralh EJ; Frank I; Tollefson MK; Thompson RH; Boorjian SA; Karnes RJ
    Eur Urol; 2014 Dec; 66(6):1116-24. PubMed ID: 25052213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
    Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
    Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Very High-Risk Localized Prostate Cancer: Outcomes Following Definitive Radiation.
    Narang AK; Gergis C; Robertson SP; He P; Ram AN; McNutt TR; Griffith E; DeWeese TA; Honig S; Singh H; Song DY; Tran PT; DeWeese TL
    Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):254-62. PubMed ID: 26853334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved decision making in intermediate-risk prostate cancer: a multicenter study on pathologic and oncologic outcomes after radical prostatectomy.
    Beauval JB; Ploussard G; Cabarrou B; Roumiguié M; Ouzzane A; Gas J; Goujon A; Marcq G; Mathieu R; Vincendeau S; Cathelineau X; Mongiat-Artus P; Salomon L; Soulié M; Méjean A; de La Taille A; Rouprêt M; Rozet F;
    World J Urol; 2017 Aug; 35(8):1191-1197. PubMed ID: 27987030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Metabolic Syndrome on Perioperative and Oncological Outcomes at Radical Prostatectomy in a Low-risk Prostate Cancer Cohort Potentially Eligible for Active Surveillance.
    Colicchia M; Morlacco A; Rangel LJ; Carlson RE; Dal Moro F; Karnes RJ
    Eur Urol Focus; 2019 May; 5(3):425-432. PubMed ID: 29306730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural History of Clinical Recurrence Patterns of Lymph Node-Positive Prostate Cancer After Radical Prostatectomy.
    Moschini M; Sharma V; Zattoni F; Quevedo JF; Davis BJ; Kwon E; Karnes RJ
    Eur Urol; 2016 Jan; 69(1):135-42. PubMed ID: 25865061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
    Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
    Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of positive surgical margins at radical prostatectomy on cancer-specific mortality in high/very high-risk prostate cancer patients with Gleason Grade Group 4-5.
    Panunzio A; Sorce G; Hoeh B; Hohenhorst L; Tappero S; Nimer N; Rajwa P; Tian Z; Terrone C; Chun FKH; Briganti A; Saad F; Shariat SF; Cerruto MA; Antonelli A; Karakiewicz PI
    Prostate; 2023 Feb; 83(3):268-276. PubMed ID: 36336728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis.
    Briganti A; Spahn M; Joniau S; Gontero P; Bianchi M; Kneitz B; Chun FK; Sun M; Graefen M; Abdollah F; Marchioro G; Frohenberg D; Giona S; Frea B; Karakiewicz PI; Montorsi F; Van Poppel H; Jeffrey Karnes R;
    Eur Urol; 2013 Apr; 63(4):693-701. PubMed ID: 22959192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radical prostatectomy for high-risk prostate cancer defined by preoperative criteria: oncologic follow-up in national multicenter study in 813 patients and assessment of easy-to-use prognostic substratification.
    Ploussard G; Masson-Lecomte A; Beauval JB; Ouzzane A; Bonniol R; Buge F; Fadli S; Rouprêt M; Rebillard X; Gaschignard N; Pfister C; Villers A; Soulié M; Salomon L;
    Urology; 2011 Sep; 78(3):607-13. PubMed ID: 21783233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
    Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
    Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic syndrome is associated with advanced prostate cancer in patients treated with radical retropubic prostatectomy: results from a multicentre prospective study.
    De Nunzio C; Simone G; Brassetti A; Mastroianni R; Collura D; Muto G; Gallucci M; Tubaro A
    BMC Cancer; 2016 Jul; 16():407. PubMed ID: 27386844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radical prostatectomy in Denmark: Survival analysis and temporal trends in clinicopathological parameters with up to 20 years of follow-up.
    Heering M; Berg KD; Brasso K; Iversen P; Røder MA
    Surg Oncol; 2017 Mar; 26(1):21-27. PubMed ID: 28317581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival after Radical Prostatectomy versus Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer.
    Chierigo F; Wenzel M; Würnschimmel C; Flammia RS; Horlemann B; Tian Z; Saad F; Chun FKH; Graefen M; Gallucci M; Shariat SF; Mantica G; Borghesi M; Suardi N; Terrone C; Karakiewicz PI
    J Urol; 2022 Feb; 207(2):375-384. PubMed ID: 34555930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
    Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
    BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer.
    Dell'Oglio P; Karnes RJ; Joniau S; Spahn M; Gontero P; Tosco L; Fossati N; Kneitz B; Chlosta P; Graefen M; Marchioro G; Bianchi M; Sanchez-Salas R; Karakiewicz PI; Poppel HV; Montorsi F; Briganti A;
    Urol Oncol; 2016 May; 34(5):234.e13-9. PubMed ID: 26706120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer.
    Briganti A; Joniau S; Gontero P; Abdollah F; Passoni NM; Tombal B; Marchioro G; Kneitz B; Walz J; Frohneberg D; Bangma CH; Graefen M; Tizzani A; Frea B; Karnes RJ; Montorsi F; Van Poppel H; Spahn M
    Eur Urol; 2012 Mar; 61(3):584-92. PubMed ID: 22153925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.